SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pgo-neil who wrote (10335)11/24/2011 12:30:42 PM
From: IRWIN JAMES FRANKEL2 Recommendations   of 10345
 
Deciding she should take T was not that hard for me. Getting her to do it was more challenging. We knew the risks. But we also faced the fact that Karen was a Copaxone failure (having become resistant) and had two serious exacerbations in a short time. So she had to change drugs. She could have gone to the ifn's. But given her frailty from a couple of decades of MS, T seemed worth the risk to go with T. At the time I could hope she was JCV-negative. We now know otherwise.

ij
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News